Serum Institute of India gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine

The DCGI has asked the company certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which has to be "scrupulously" fo...

Reuters
India’s drug regulator on Tuesday gave permission to Serum Institute of India (SII) to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country. The drug controller had earlier put on hold the trials after an adverse event was reported in a participant.

The DCGI on Tuesday revoked its earlier order of suspending any new recruitment for phase two and three trial.
The permission however comes with a caveat. The DCGI has asked the company certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which has to be "scrupulously" followed by Serum Institute of India (SII).


SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.

The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford COVID-19 vaccine candidate till further orders after AstraZeneca halted the clinical trials in other countries because of "an unexplained illness" in a participant in the study.

On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said it had resumed the trials for their coronavirus vaccine in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

Related Companies

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+